Three items of pandemic news you may have missed recently: Kids and Covid-19; enhanced lethality of the B.1.1.7 variant; and more on the pause in AstraZeneca shots as Europe investigates a rare condition. Plus news briefs and a frippery. AstraZeneca … Continue reading →
Herewith three items of pandemic news you may have missed recently: Controlling the message on vaccines of different efficacy; Johnson & Johnson’s day in the spotlight; and media jumping the gun on viral variant stories. Plus news briefs and a … Continue reading →
Three items of pandemic news you may have missed recently: FDA signals a streamlined approval path for vaccine updates; South Africa halts AstraZeneca distribution; and Moderna demonstrates its shot’s efficacy against viral variants. Plus news briefs and a frippery. Moderna’s … Continue reading →
Herewith three items of pandemic news you may have missed recently: A trial of mixed shots begins in the UK; a sobering tale of a variant’s spread; and J&J applies for an EUA. Plus news briefs and a frippery. Johnson … Continue reading →
Herewith three items of pandemic news you may have missed recently: The South African variant shows up in the US; pharma giants are helping each other out; and Novavax reads out preliminary results. Plus news briefs and a frippery. Novavax … Continue reading →
The FDA’s outside committee of experts, the VRBPAC, is meeting again today, one week after they voted to authorize the Pfizer / BioNTech vaccine. Pretty much everyone expects that the committee will give the nod to Moderna’s candidate this afternoon. … Continue reading →
As expected, on Thursday the FDA’s panel of outside advisors recommended that Pfizer / BioNTech’s vaccine candidate, BNT162b2, be granted an emergency use authorization. The vote was 17 to 4 with one abstention. The committee that met (all day) yesterday … Continue reading →
Here are three more items of pandemic news you may have missed recently: US vaccine willingness is on the rise; it’s OK for infected mothers and newborns to cohabit; and the first virus authorization is imminent. Plus a frippery. First … Continue reading →
The biggest drawback to one of the vaccine candidates receiving an FDA Emergency Use Authorization: it would halt the Phase III trial and destroy any chance of getting more data about that vaccine’s safety, efficacy, and longevity. On the This … Continue reading →
The President, always one to say the quiet parts out loud, has made no secret of wanting to announce a vaccine before November 3 in order to boost his chances for reelection. Let’s look at how that might be possible. … Continue reading →
